Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

28.80 +0.07 (+0.23%)
Streaming Delayed Price Updated: 2:56 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗
Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide. 
Via The Motley Fool
News headline image
The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism
By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,... 
Via Finterra
Topics Artificial Intelligence Economy Energy
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
Via The Motley Fool
Topics Regulatory Compliance
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗
Via Chartmill
Why Is TEVA Stock Rising Pre-Market Today? ↗
Via Stocktwits
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
The 3 Best Stocks to Invest $1,000 in Right Now ↗
These three high-quality stocks have ample growth potential. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗
Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF). 
Via The Motley Fool
Topics Artificial Intelligence ETFs Retirement
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
The Best Healthcare Stock to Invest $1,000 in Right Now ↗
There's nothing generic about this drugmaker's recent performance and continued prospects. 
Via The Motley Fool
News headline image
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗
Sorry, Teva, it's not you ... it's me. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
News headline image
Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗
This specialty retailer delivers personal care and home fragrance products through a broad network of stores and online channels. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year ↗
Albertsons operates a nationwide grocery network, pairing in-house food production with a broad mix of retail and pharmacy services. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗
This technology firm offers cloud-based data management and compliance tools for organizations using Microsoft 365 and other platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment ↗
The application was based on data from a late-stage trial in which TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently... 
Via Stocktwits
News headline image
CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗
The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 
Via Stocktwits
Topics Intellectual Property
News headline image
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
Via Finterra
Topics Economy World Trade
News headline image
Teva (TEVA) Q4 2024 Earnings Call Transcript ↗
Teva (TEVA) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Teva (TEVA) Q3 2024 Earnings Call Transcript ↗
Teva (TEVA) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗
Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗
Aytu BioPharma AYTU Q2 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗
The Invesco KBW Bank ETF tracks a sector-specific index of leading U.S. banking firms, emphasizing large and regional institutions. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Teva (TEVA) Q3 2025 Earnings Call Transcript ↗
Teva (TEVA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026
NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while... 
Via MarketMinute
Topics Earnings Economy Government
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of... 
Via Finterra
Topics Earnings Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.